Celcuity Inc. shares fall 2.09% premarket after insider sells $4.82 million in stock.
ByAinvest
Tuesday, Aug 5, 2025 6:56 am ET1min read
CELC--
Celcuity Inc. declined 2.09% in premarket trading, with the company's recent news events including a corporate presentation on unlocking the potential of treating cancers involving the PI3K/AKT/mTOR pathway. The presentation highlighted the success of gedatolisib triplet and doublet therapies in improving median progression-free survival (mPFS) in patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer. Additionally, Celcuity's stock has seen significant volatility with insider selling and public offerings, which may have contributed to the stock's decline.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet